Search results
Showing 946 to 960 of 1490 results for patients and public
This guideline covers the routine postnatal care that women and their babies should receive in the first 8 weeks after the birth. It includes the organisation and delivery of postnatal care, identifying and managing common and serious health problems in women and their babies, how to help parents form strong relationships with their babies, and baby feeding. The recommendations on emotional attachment and baby feeding also cover the antenatal period.
Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.
Ovarian cancer: identifying and managing familial and genetic risk (NG241)
This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.
Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]
Awaiting development Reference number: GID-TA11307 Expected publication date: 06 January 2027
Leriglitazone for treating cerebral adrenoleukodystrophy in boys and men 2 years and over [ID3903]
In development Reference number: GID-TA11445 Expected publication date: TBC
Awaiting development Reference number: GID-TA11773 Expected publication date: 27 May 2027
Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)
Evidence-based recommendations on letermovir (Prevymis) for preventing cytomegalovirus disease after a stem cell transplant.
Our framework agreement allows UK NHS, health and social care organisations to buy knowledge resources that support practice, learning and development.
This process guide provides an overview of the key principles used for developing NICE decision aids. It ensures that robust, quality-assured decision aids for people using and providing health and social care services are developed in an open, transparent and timely way, with appropriate input from key groups
Workplace health: long-term sickness absence and capability to work (NG146)
This guideline covers how to help people return to work after long-term sickness absence, reduce recurring sickness absence, and help prevent people moving from short-term to long-term sickness absence.
Awaiting development Reference number: GID-TA11437 Expected publication date: TBC
Awaiting development Reference number: GID-TA11637 Expected publication date: TBC
In development Reference number: GID-TA11635 Expected publication date: 26 August 2026
In development Reference number: GID-IPG10441 Expected publication date: 17 December 2026
Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)
Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.